BETA DRUGS LIMITED (BETA) financials

BETA DRUGS LIMITED (BETA) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

Market Cap: ₹1,906Cr.
Current Price: ₹1,720
Stock P/E: 119
ROE: 10.3%
ROCE: 11.2%
Book Value: ₹148
Dividend Yield: 0.00%
52W High / Low: ₹2,808/990

In Jun 2026, BETA DRUGS LIMITED (BETA) reported sales ₹55.83 Cr and net profit ₹5.93 Cr.

Annual TTM: sales ₹215 Cr, net profit ₹16 Cr.

Shareholding: Promoters 58.91% (Sep 2026), FIIs 1.37% (Sep 2026), DIIs 6.45% (Sep 2026), Public 33.27% (Sep 2026), No. of Shareholders 10,145% (Sep 2026).

BETA quarterly results (₹ Cr.)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	48.27	53.74	66.32	54.48	50.28	54.35	55.83
Expenses	42.55	48.49	58.80	49.75	43.74	44.60	45.68
Operating Profit	5.72	5.25	7.52	4.73	6.54	9.75	10.15
OPM %	11.85%	9.77%	11.34%	8.68%	13.01%	17.94%	18.18%
Other Income	-1.47	1.71	2.97	2.74	2.51	2.92	1.87
Interest	1.33	2.81	2.79	2.97	3.17	2.87	1.60
Depreciation	1.92	2.14	2.04	2.38	2.51	2.74	2.49
Profit before tax	1.00	2.01	5.66	2.12	3.37	7.06	7.93
Tax %	25.00%	30.85%	25.09%	28.77%	3.56%	24.50%	25.22%
Net Profit	0.75	1.39	4.23	1.51	3.25	5.33	5.93
EPS in Rs	0.74	1.38	4.19	1.50	3.21	5.26	5.35
Raw PDF	—	—	—	—	—	—	—

BETA profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	65	79	125	158	197	220	225	215
Expenses	54	64	99	126	164	189	197	184
Operating Profit	12	15	25	31	34	31	29	31
OPM %	18%	19%	20%	20%	17%	14%	13%	14%
Other Income	0	1	1	1	2	2	11	10
Interest	1	1	0	1	1	5	12	11
Depreciation	3	5	5	6	5	7	10	10
Profit before tax	9	10	20	25	29	21	18	20
Tax %	21%	29%	29%	25%	26%	26%	21%	—
Net Profit	7	7	14	19	22	15	14	16
EPS in Rs	7.03	6.91	14.11	18.63	21.72	15.29	14.14	15.32
Dividend Payout %	-0%	-0%	-0%	-0%	-0%	-0%	-0%	—

BETA balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	9	10	10	10	10	10	10	10
Reserves	32	47	54	68	87	106	119	139
Borrowings	8	9	5	7	6	6	128	130
Other Liabilities	16	17	18	27	32	49	60	55
Total Liabilities	65	82	86	111	134	170	317	335
Fixed Assets	12	32	28	34	35	36	53	76
CWIP	15	0	2	-0	-0	-0	-0	-0
Investments	2	6	7	7	7	6	6	6
Other Assets	36	44	50	70	93	128	257	254
Total Assets	65	82	86	111	134	170	317	335

BETA cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	8	6	12	19	10	21	18	19
Cash from Investing Activity	-16	-14	-3	-13	-6	-11	-21	-31
Cash from Financing Activity	-1	9	-4	1	-2	-1	118	-11
Net Cash Flow	-9	1	4	7	2	9	115	-24
Free Cash Flow	-7	-1	8	9	3	15	-6	-13
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	75%	52%	76%	74%	33%	63%	57%	67%

BETA shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	66.73%	66.73%	66.73%	66.73%	64.90%	64.63%	59.10%	58.91%
FIIs	1.15%	0.90%	0.90%	0.90%	1.14%	1.16%	1.02%	1.37%
DIIs	0.17%	0.17%	0.26%	0.29%	1.90%	2.15%	6.23%	6.45%
Public	31.95%	32.20%	32.11%	32.07%	32.07%	32.06%	33.65%	33.27%
No. of Shareholders	2,882	3,054	3,139	3,184	3,694	4,736	7,359	10,145

BETA key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	109	117	96	92	101	93	81	87
Inventory Days	76	64	65	44	60	71	84	94
Days Payable	121	97	111	101	102	116	124	132
Cash Conversion Cycle	64	84	49	34	59	48	41	49
Working Capital Days	62	65	81	63	83	72	68	74
ROCE %	18%	17%	16%	27%	28%	27%	16%	11%

BETAUpdated 20 Oct 2026, 6:46

Beta Drugs Limited

BETAUpdated 20 Oct 2026, 6:46

Market Cap

₹1,906Cr.

Current Price

₹1,720

High / Low

₹2,808/990

Stock P/E

119

ROE10.3%

ROCE11.2%

Book Value₹148

Face Value₹10.0

Dividend Yield0.00%

About

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Dec 2024	48.27	1.33	42.55	-1.47	1.92	1	25	0.75	0.74
Mar 2025	53.74	2.81	48.49	1.71	2.14	2.01	30.85	1.39	1.38
Jun 2025	66.32	2.79	58.8	2.97	2.04	5.66	25.09	4.23	4.19
Sep 2025	54.48	2.97	49.75	2.74	2.38	2.12	28.77	1.51	1.5
Dec 2025	50.28	3.17	43.74	2.51	2.51	3.37	3.56	3.25	3.21
Mar 2026	54.35	2.87	44.6	2.92	2.74	7.06	24.5	5.33	5.26
Jun 2026	55.83	1.6	45.68	1.87	2.49	7.93	25.22	5.93	5.35

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	0	0	0	0	0	0	0	0	-0.17
Mar 2016	26	1	23	0	1	1	0	1	1.74
Mar 2017	42	1	34	0	1	5	19	4	6.57
Mar 2018	51	1	41	0	2	7	1	7	7.43
Mar 2019	58	1	48	0	2	7	-3	8	8.47
Mar 2020	65	1	54	0	3	9	21	7	7.03
Mar 2021	79	1	64	1	5	10	29	7	6.91
Mar 2022	125	0	99	1	5	20	29	14	14.11
Mar 2023	158	1	126	1	6	25	25	19	18.63
Mar 2024	197	1	164	2	5	29	26	22	21.72
Mar 2025	220	5	189	2	7	21	26	15	15.29
Mar 2026	225	12	197	11	10	18	21	14	14.14
TTM	215	11	184	10	10	20	—	16	15.32

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	58.91%
FIIs	1.37%
DIIs	6.45%
Public	33.27%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	66.73%	0.32%	0.02%	32.92%
Mar 2024	66.73%	0.32%	0.06%	32.87%
Jun 2024	66.73%	0.9%	0.12%	32.25%
Sep 2024	66.73%	1.16%	0.16%	31.95%
Dec 2024	66.73%	1.15%	0.17%	31.95%
Mar 2025	66.73%	0.9%	0.17%	32.2%
Jun 2025	66.73%	0.9%	0.26%	32.11%
Sep 2025	66.73%	0.9%	0.29%	32.07%
Dec 2025	64.9%	1.14%	1.9%	32.07%
Mar 2026	64.63%	1.16%	2.15%	32.06%
Jun 2026	59.1%	1.02%	6.23%	33.65%
Sep 2026	58.91%	1.37%	6.45%	33.27%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	1	0	5	2	8	1	6	0	2	8
Mar 2016	1	1	8	5	15	7	0	0	8	15
Mar 2017	1	5	8	9	23	8	0	0	15	23
Mar 2018	9	24	8	9	50	13	1	0	35	50
Mar 2019	9	32	8	16	65	12	15	2	36	65
Mar 2020	10	47	9	17	82	32	0	6	44	82
Mar 2021	10	54	5	18	86	28	2	7	50	86
Mar 2022	10	68	7	27	111	34	0	7	70	111
Mar 2023	10	87	6	32	134	35	0	7	93	134
Mar 2024	10	106	6	49	170	36	0	6	128	170
Mar 2025	10	119	128	60	317	53	0	6	257	317
Mar 2026	10	139	130	55	335	76	0	6	254	335

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	1	-6	4	0
Mar 2016	0	-2	3	0
Mar 2017	5	-2	-3	0
Mar 2018	17	-11	5	12
Mar 2019	8	-16	-1	-9
Mar 2020	6	-14	9	1
Mar 2021	12	-3	-4	4
Mar 2022	19	-13	1	7
Mar 2023	10	-6	-2	2
Mar 2024	21	-11	-1	9
Mar 2025	18	-21	118	115
Mar 2026	19	-31	-11	-24

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	112	61	92	104	109	117	96	92	101	93	81	87
Inventory Days	3,115	69	37	38	76	64	65	44	60	71	84	94
Days Payable	5,256	97	108	82	121	97	111	101	102	116	124	132
Cash Conversion Cycle	-2,029	33	21	60	64	84	49	34	59	48	41	49
Working Capital Days	-758	-19	17	50	62	65	81	63	83	72	68	74
ROCE %	-3%	22%	49%	29%	18%	17%	16%	27%	28%	27%	16%	11%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of BETA DRUGS LIMITED (BETA)?

The reported market capitalisation for BETA DRUGS LIMITED (BETA) is ₹1,906Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of BETA?

The current price shown for BETA DRUGS LIMITED (BETA) on Fincrux is ₹1,720 with a 52-week high/low of ₹2,808/990.

What is the P/E ratio of BETA DRUGS LIMITED (BETA)?

The stock P/E for BETA DRUGS LIMITED (BETA) is 119 on Fincrux, with ROE at 10.3% and ROCE at 11.2%.

What were BETA latest quarterly results?

For Jun 2026, BETA DRUGS LIMITED (BETA) reported sales ₹55.83 Cr and net profit ₹5.93 Cr (figures in ₹ crore unless noted).

What are BETA annual sales and net profit?

For TTM, BETA DRUGS LIMITED (BETA) shows sales of ₹215 Cr and net profit of ₹16 Cr on the Fincrux profit & loss statement.

Who owns BETA DRUGS LIMITED (BETA)?

Latest shareholding for BETA DRUGS LIMITED (BETA) on Fincrux: Promoters 58.91% (Sep 2026), FIIs 1.37% (Sep 2026), DIIs 6.45% (Sep 2026), Public 33.27% (Sep 2026), No. of Shareholders 10,145% (Sep 2026).

Where can I find BETA DRUGS LIMITED (BETA) financials?

BETA DRUGS LIMITED (BETA) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show BETA balance sheet and cash flow?

Yes. The BETA DRUGS LIMITED (BETA) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 20 October 2026 at 6:46